Jacobien R. Hilberink

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability.

High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability.

Journal: Signal transduction and targeted therapy
Published: September 07, 2024

A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.

A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.

Journal: British journal of haematology
Published: February 09, 2024

Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population.

Thiostrepton induces cell death of acute myeloid leukemia blasts and the associated macrophage population.

Journal: Haematologica
Published: May 23, 2023

M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

Journal: Science advances
Published: April 14, 2023

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Journal: Blood cancer journal
Published: March 26, 2023

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.

Journal: Blood cancer journal
Published: August 31, 2022

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation
Published: November 22, 2020

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

Journal: Blood advances
Published: October 19, 2020

Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy.

Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy.

Journal: Transplantation and cellular therapy
Published: October 06, 2020

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Journal: Leukemia research
Published: November 15, 2018

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Journal: Cancer medicine
Published: June 29, 2018
Showing 1-11 of 11

Last Updated: 09/26/2026